...(audio in progress) 2025 RBC Global Healthcare Conference. My name is Greg Renza, one of the biotech analysts. And we're pleased to close out our day with Fulcrum Therapeutics. Joining us from the company is the CEO, Alex Sapir. Alex, great to see you. And of course the Head of Early Development, Iain Fraser. Iain, it's great to see you as well. We're certainly at a really important point for Fulcrum in 2025 with some data coming, but maybe Alex, we can just take a step back, and for those less acquainted with Fulcrum, just give a brief introduction to the company, please. Alex Sapir ...